3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Melanoma
106
Carcinoma, Non-Small-Cell Lung
34
Carcinoma, Renal Cell
23
Prostatic Neoplasms
17
Neoplasms
15
Brain Neoplasms
15
Neoplasm Metastasis
14
Lung Neoplasms
12
Breast Neoplasms
11
Uveal Melanoma
10
Pancreatic Neoplasms
10
Sarcoma
9
Small Cell Lung Carcinoma
7
Urinary Bladder Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
6
Kidney Neoplasms
6
Diabetes Mellitus, Insulin-Dependent, 12
6
Carcinoma, Transitional Cell
6
Carcinoma, Hepatocellular
6
Skin Neoplasms
5
Ovarian Neoplasms
5
Histiocytoma, Malignant Fibrous
5
Colorectal Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Recurrence
4
Neuroendocrine Tumors
4
Mesothelioma
4
Glioblastoma
4
Colonic Neoplasms
4
Interventions
Imatinib Mesylate
4
Gemcitabine
2
Doxorubicin
2
Docetaxel
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
saracatinib
1
pembrolizumab
1
pazopanib
1
envafolimab
1
TTI-621
1
Sunitinib
1
Razoxane
1
Radiotherapy, Intensity-Modulated
1
Radiation Dose Hypofractionation
1
Quality of Life
1
Polymerase Chain Reaction
1
Neoadjuvant Therapy
1
MLN 8237
1
Ipilimumab
1
Gene Expression Profiling
1
Dexrazoxane
1
Dactinomycin
1
Blotting, Western
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Dermatofibrosarcoma
×
Ipilimumab
×
Clear all
NCT04480502
2024-05-17
ENVASARC
Tracon Pharmaceuticals Inc.
Phase 2
Active not recruiting
207 enrolled